Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 45Breast Neoplasms 15Leiomyoma 3Cardiovascular Diseases 3Polycystic Ovary Syndrome 2Neoplasms 2Endometrial Neoplasms 2Advanced Breast Cancer 2Stage II Prostate Adenocarcinoma 1Sexual Dysfunctions, Psychological 1Sarcopenia 1Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms, Castration-Resistant 1Prostatectomy 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Pelvic Pain 1Oligometastatic Prostate Carcinoma 1Obesity 1Non-alcoholic Fatty Liver Disease 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Metabolic Syndrome 1Metabolic Diseases 1Kallmann Syndrome 1Inflammatory Breast Neoplasms 1Infertility 1Hypogonadism 1Hyperprolactinemia 1

Interventions

abiraterone 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oligometastatic Prostate Carcinoma × Gonadotropin-Releasing Hormone × Clear all
NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic

Phase 2 Recruiting
110 enrolled
Genitourinary

Oligometastatic Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡